Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04437472 · ClinicalTrials.gov registry record

Remote Collection of Patient Reported Toxicity Using SMS Text Messaging (CareSignal)

A clinical trial, sponsored by Washington University School of Medicine.

Completed
Registry status
30
Enrollment target

NCT04437472: Completed study, sponsored by Washington University School of Medicine.

NCT04437472 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04437472 has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
30 participants
Enrollment target

Study Summary

CareSignal has developed an application that allows for remote collection of patient-reported data such as symptoms or outcomes on any device compatible with the short message service (SMS), otherwise known as "text messaging". The software can be configured to complete symptom monitoring by surveying patients about toxicity using the PRO-CTCAE tools. PRO-CTCAE is the patient reported outcomes version of the CTCAE that was designed by the National Cancer Institute (NCI) for use in clinical trials.

Interventions

  • OTHER CareSignal

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2020-09-22
Est. Completion 2021-07-09

What the finished NCT04437472 record still lists

NCT04437472 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which CareSignal is the first listed.

NCT04437472 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04437472 about?

NCT04437472 is a clinical study titled "Remote Collection of Patient Reported Toxicity Using SMS Text Messaging (CareSignal)". CareSignal has developed an application that allows for remote collection of patient-reported data such as symptoms or outcomes on any device compatible with the short message service (SMS), otherwise known as "text messaging". The software can be configured to complete symptom monitoring by surveyi...

What is the current status of trial NCT04437472?

This trial is currently completed. The enrollment target is 30 participants. The study started on 2020-09-22. Estimated completion is 2021-07-09.

What interventions are being tested in trial NCT04437472?

The interventions under investigation include: CareSignal (OTHER).

Who is sponsoring clinical trial NCT04437472?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04437472, the US trial registry maintained by the National Library of Medicine. NCT04437472 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.